Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amlitelimab dose-ranging study in adults with moderate-to-severe asthma
jRCT2031220538Completed
- Sponsor
- Sanofi
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Randomised, double-blind trial of amlitelimab in asthma (4 arms), sponsored by Sanofi. Primary endpoint: Annualized rate of severe exacerbation events over 48 weeks. Started Jan 2023; status: completed.
02
Drugs
amlitelimab
03
Conditions
asthma
Beyond the preview
Go deeper on jRCT2031220538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220538.